Novo Nordisk A S annual revenue
2019
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Revenue Growth & History (NVO)
Novo Nordisk A S reported kr309.06B in revenue for fiscal 2025, an increase of 6.43% from the previous fiscal year.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | kr309.06B | kr18.66B | +6.43% |
| 2024 | 2024-12-31 | kr290.40B | kr58.14B | +25.03% |
| 2023 | 2023-12-31 | kr232.26B | kr55.31B | +31.26% |
| 2022 | 2022-12-31 | kr176.95B | kr36.15B | +25.68% |
| 2021 | 2021-12-31 | kr140.80B | kr13.85B | +10.91% |
| 2020 | 2020-12-31 | kr126.95B | kr4.92B | +4.04% |
| 2019 | 2019-12-31 | kr122.02B | — | — |
Novo Nordisk A S quarterly revenue
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | kr78.49B | kr1.63B | +2.12% |
| Q1 2026 | 2026-03-31 | kr96.82B | kr18.74B | +23.99% |
| Q4 2025 | 2025-12-31 | kr79.14B | −kr6.54B | −7.63% |
| Q3 2025 | 2025-09-30 | kr74.98B | kr3.67B | +5.14% |
| Q2 2025 | 2025-06-30 | kr76.86B | kr8.80B | +12.93% |
| Q1 2025 | 2025-03-31 | kr78.09B | kr12.74B | +19.49% |
| Q4 2024 | 2024-12-31 | kr85.68B | — | — |
| Q3 2024 | 2024-09-30 | kr71.31B | — | — |
| Q2 2024 | 2024-06-30 | kr68.06B | — | — |
| Q1 2024 | 2024-03-31 | kr65.35B | — | — |
Novo Nordisk A S revenue growth trends
Over the last five reported fiscal years, revenue grew from kr126.95B to kr309.06B, a compound annual growth rate of 19.48%. Novo Nordisk A S's latest reported quarter, Q2 2026, generated kr78.49B in revenue, an increase of 2.12% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Novo Nordisk A S source filings ↗Community posts
Novo licenses early-stage weekly obesity pill for $300 million upfront
Novo Nordisk ($NVO) has agreed to license Hengrui Pharma’s HRS-1596, an experimental oral medicine targeting both GLP-1 and GIP receptors. The agreement includes $300 million upfront within a potential $2.6 billion total, with the balance d ...
Novo Nordisk sets new pipeline and manufacturing ambitions
Novo Nordisk ($NVO) outlined ambitions to launch more than five major new medicines by 2030 and generate over DKK150 billion in risk-adjusted sales from its current pipeline by 2035. It also intends to enter or complete at least five Phase ...
Novo’s weekly growth-hormone treatment gains another European recommendation
Novo Nordisk ($NVO) received a positive European advisory opinion for once-weekly Sogroya in children with idiopathic short stature and persistent growth disturbance. The proposed expansion is supported by the REAL8 study, which found the w ...
Novo Nordisk receives positive European opinion for hemophilia treatment
Novo Nordisk ($NVO) received a positive recommendation from the European Medicines Agency’s human medicines committee for FREHEMGO, its denecimig treatment for hemophilia A. The proposed indication covers adults and children, including pati ...
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...
